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of the clinical and mutational spectrum and description
of the natural history
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Purpose: In 2012 we reported in six individuals a clinical condi-
tion almost indistinguishable from PLOD1-kyphoscoliotic Ehlers–
Danlos syndrome (PLOD1-kEDS), caused by biallelic mutations
in FKBP14, and characterized by progressive kyphoscoliosis, myo-
pathy, and hearing loss in addition to connective tissue abnor-
malities such as joint hypermobility and hyperelastic skin. FKBP14 is
an ER-resident protein belonging to the family of FK506-binding
peptidyl-prolyl cis–trans isomerases (PPIases); it catalyzes the folding
of type III collagen and interacts with type III, type VI, and type X
collagens. Only nine affected individuals have been reported to date.
Methods: We report on a cohort of 17 individuals with FKBP14-
kEDS and the follow-up of three previously reported patients, and
provide an extensive overview of the disorder and its natural history
based on clinical, biochemical, and molecular genetics data.
Results: Based on the frequency of the clinical features of 23
patients from the present and previous cohorts, we define major
and minor features of FKBP14-kEDS. We show that myopathy is
confirmed by histology and muscle imaging only in some patients,
and that hearing impairment is predominantly sensorineural and
may not be present in all individuals.
Conclusion: Our data further support the extensive clinical overlap
with PLOD1-kEDS and show that vascular complications are rare
manifestations of FKBP14-kEDS.
Genet Med advance online publication 15 June 2017
KeyWords: diagnostic criteria; FKBP14; FKBP22; kyphoscoliotic
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INTRODUCTION
Ehlers–Danlos syndrome (EDS) comprises a heterogeneous spec-
trum of monogenic conditions with multisystemic and variable
clinical manifestations affecting primarily the skin, ligaments and
joints, blood vessels, and internal organs. Symptoms are usually
present in early childhood and the clinical spectrum varies from
mild skin and joint hyperlaxity to intermediate and severe
physical disability and life-threatening complications.1,2
To date, the 1997 Villefranche classification of EDS has
recognized six types based on clinical phenotype, inheritance
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pattern, and underlying biochemical and molecular defect(s).1
Among them, the kyphoscoliotic type of EDS (MIM 225400)
was recognized as one distinct type based on the following
characteristic clinical features: severe muscular hypotonia
at birth; generalized joint laxity; kyphoscoliosis at birth,
which is progressive; scleral fragility; and rupture of the
ocular globe. The disorder, which is currently called by the
2017 International Nosology of EDS PLOD1-kyphoscoliotic
EDS (PLOD1-kEDS),3 is caused by the deficiency of the
collagen-modifying enzyme procollagen-lysine, 2-oxoglut-
arate 5-dioxygenase 1 (PLOD1 or LH1, lysyl hydroxylase 1),
which leads to an abnormal pattern of urinary pyridinoline
crosslinks and thus to an increased ratio of lysyl-pyridinoline
to hydroxylysyl-pyridinolines.2
Recently, individuals with a clinical phenotype almost
indistinguishable from PLOD1-kEDS but with a normal ratio
of total urinary lysyl-pyridinoline and hydroxylysyl-pyridino-
lines, and causative biallelic nonsense variants in FKBP14
(MIM 614557), have been reported as a new condition,4
expanding the increasing genetic heterogeneity of EDS
conditions. The first six affected individuals were reported
to have muscle hypotonia at birth, progressive scoliosis, joint
hypermobility, hyperelastic skin, gross motor developmental
delay, myopathy, and sensorineural hearing impairment.4
Vascular complications such as dissections and occlusions
in medium-sized vessels, and tortuosity of the arterial tree
have been recently described in two further patients,
expanding the clinical spectrum of FKBP14-kEDS.5,6 Because
of severe early-onset muscle hypotonia and delayed motor
development, children with FKBP14-kEDS usually undergo
extensive neuromuscular workup in the neonatal period. Light
and electron microscopic studies of muscle biopsies showed
mild to moderate histological abnormalities and focal
myofibrillar rearrangements and Z-line anomalies, respec-
tively, albeit without a specific recognizable pattern.4
Furthermore, muscle magnetic resonance imaging (MRI)
findings are indicative of fatty degeneration of muscle tissue,
which is a typical feature of myopathies and muscular
dystrophies.7,8 Primary myopathies caused by mutations in
collagen such as the type VI (COL6) collagenopathy Ullrich
congenital muscular dystrophy (MIM 254090) may show
substantial connective-tissue involvement including kyphos-
coliosis, joint hypermobility, joint contractures, and abnormal
scar formation;9–13 however, skin hyperextensibility is absent
and motor function does not improve with age. Hence, the
PLOD1-kEDS and Ullrich congenital muscular dystrophy are
major differential diagnoses to FKBP14-kEDS.
FKBP14 encodes for FKBP14 (alias FKBP22; Q9NWM8) a
22 kDa protein that belongs to the FK506-binding protein
(FKBP)-family of peptidyl-prolyl cis–trans isomerases
(PPIases). The protein catalyzes the folding of type III
collagen and interacts with type III, type VI, and type X
collagens, thus helping to explain the broad phenotype
observed in the patients characterized so far.14 Up to now
only nine patients have been reported with this ultrarare
connective tissue disorder. Here we report on the clinical,
biochemical, and molecular findings of an additional 17
individuals from 15 unrelated families diagnosed with
FKBP14-kEDS. These individuals currently represent the
largest cohort of FKBP14-kEDS and thus allow an in-depth
characterization of the clinical features also including the
natural history. In comparison to the clinical features reported
so far, the characteristic features are emphasized and the
clinical presentation is refined. The molecular data include
two newly identified nonsense variants, and the hitherto first
FKBP14 p.Met48Lys missense variant. The pathogenicity of
this mutation is supported by conservation analysis, predic-
tion software, and its mapping on the available crystal
structure of the protein. This finding suggests that complete
or partial loss of function of FKBP14 is the crucial
pathological mechanism of this disorder.
MATERIALS AND METHODS
Clinical and neuromuscular investigations
Clinical information was obtained through a questionnaire
that was sent to each involved center and subsequently
analyzed centrally. Clinical examinations were in most cases
performed by geneticists, neurologists, or pediatricians. In
several cases an initially suspected diagnosis of a neuro-
muscular disorder could be excluded by neuromuscular
workup, while in others, the differential diagnosis of
PLOD1-kEDS could be ruled out by urinary pyridinoline
analysis. For all studies, informed consent of the patients or
their parents, in accordance with requirements of the local
ethics committees of the referring physicians, was obtained.
Biochemical and laboratory analyses
Total urinary pyridinoline crosslinks, lysyl pyridinoline
and hydroxylysyl pyridinoline, were measured by high-
performance liquid chromatography as described.15,16
Molecular genetic studies
Genomic DNA was isolated from peripheral blood leukocytes
using standard procedures.
For 14 of 17 patients, mutation analysis of the coding
region and the flanking intron–exon boundaries of FKBP14
(RefSeq accession number NG_032173.1 (genomic) and
NM_017946.3 (mRNA)) was performed by polymerase chain
reaction and direct Sanger sequencing as previously
described.4
For transcript analysis, total RNA was extracted from
fibroblasts of P5/FIV and cDNA synthesis and polymerase
chain reaction were performed according to standard
protocols.
Targeted exome sequencing using SureSelectXT (Agilent
Technologies, Santa Clara, CA, USA) and MiSeq platform
(Illumina, San Diego, CA, USA) was used to analyze the
coding regions and intron/exon boundaries of a panel of
genes associated with kyphoscoliosis (B4GALT7, CHST14,
FKBP14, PLOD1, PRDM5, RIN2, SLC39A13, and ZNF469).
Mutations were confirmed by Sanger sequencing. Nucleotide
numbering starts with + 1, which corresponds to the first
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ATG translation initiation codon at position 294 of the
reference sequence NM_017946.3, whereas amino acid
residues are numbered from the first methionine residue of
the reference sequence NP_060416.1
Mapping of the FKBP14 Met48Lys missense variant onto
the crystal structure
The methionine residue 48 (Met48), which was found to be
mutated to lysine (Lys) in one patient, was mapped onto the
1.9-Å resolution crystal structure of human peptidyl-prolyl
cis–trans isomerase FKBP14 (Protein Data Bank, 4MSP)17
using MolSoft MolBrowser 3.8-5.
RESULTS
Clinical and genetic findings of selected patients based
either on newly recognized clinical features or new
pathogenic variants
The disease-causing variants identified in the patient cohort
are mapped onto the FKBP14 protein structure and shown in
Supplementary Figure S4A online. Clinical and genetic
findings of selected patients are listed in Table 1.
Patient P2/FII
Patient 2/FII (Figure 1d) is a 9-year-old girl, born to
consanguineous first-cousin parents of Iranian origin, who
presented at birth with severe congenital hypotonia. She
showed bilateral clubfoot; motor developmental delay; severe
muscle weakness with a positive Gowers’ sign; progressive
severe scoliosis that required surgical intervention; severe
joint hypermobility of fingers, wrists, and toes; soft skin; easy
bruising; normal hearing; nasal speech; and dysarthria.
Independent walking was achieved at the age of 7 years.
Sequencing of FKBP14 revealed a novel homozygous
c.143 T>A substitution in exon 1 causing a p.(Met48Lys)
mutation. Both parents were carriers of this variant. This
missense mutation is not reported in the browser of the
Exome Aggregation Consortium (http://exac.broadinstitute.
org) and it is likely to be disease-causing according to the
prediction software SIFT and Mutation Taster, or potentially
benign according to PolyPhen2. The amino acid residue
Met48 is conserved from human to birds (BLASTP search).
Mapping of Met48 on the three-dimensional structure of
FKBP14 (PDB 4MSP) reveals that the amino acid is localized
near the putative PPIase active site amino acids tyrosine 52
(Y52), isoleucine 75 (I75), tryptophan 88 (W88), and
phenylalanine 127 (F127) (Supplementary Figure S4B).
Patients P5/FIV and P6/FIV
P5/FIV is the first child of healthy consanguineous first-
cousin parents of Pakistani origin. He was born by emergency
Cesarean section for fetal bradycardia, following spontaneous
rupture of membranes and premature labor at 31 weeks
gestation. On clinical examination he was noted to have a very
wide cleft palate, mild micrognathia, and a large anterior
fontanel. He had clenched hands with bilateral single palmar
creases, overlapping fingers, and tightly adducted thumbs;
mild flexion contractures of the elbows and knees; and
bilateral talipes equinovarus, with prominent heels and left-
sided developmental dysplasia and dislocation of the hip. He
also had a large umbilical hernia and right inguinal hernia. He
was breathing spontaneously at birth, but at the age of 3 days,
he required intubation and mechanical ventilation. A
tracheostomy was inserted because of upper airway obstruc-
tion and he was ventilated for 6 months. The tracheostomy
was removed at the age of 7 years. He had gastroesophageal
reflux and required long-term nasogastric feeding followed by
insertion of percutaneous endoscopic gastrostomy and
fundoplication at the age of 2 years. He had motor delay
and first sat unsupported at the age of 12 months and walked
at the age of 3 years. On examination at the age of 2 years
6 months, the limb contractures had resolved, and he had
marked generalized joint laxity and poor muscle bulk. His
skin was soft and velvety, but not hyperextensible. There was
hypertrichosis of the arms, legs, and at the base of the spine.
He had long fingers. There was pectus carinatum and
kyphoscoliosis. Due to bilateral sensorineural hearing loss
he received a cochlear implant in the right ear at age 6 years.
P6/FIV is the 4-year-old brother of P5/FIV. Talipes and
polyhydramnios were noted antenatally. He was born by
emergency Cesarean section at 38 weeks gestation and
required intubation and ventilation on the first day of life.
He was floppy at birth and had clenched hands and
overlapping fingers. He was noted to have micrognathia,
but not cleft palate. He passed his neonatal hearing screen. On
examination, at the age of 7 months, he had mild
hypertrichosis and esotropia. There was marked, generalized
joint hypermobility and poor muscle bulk. He had “criss-
cross” markings on his palms and soles. He also had a small
mouth and deep-set eyes. He developed gastroesophageal
reflux and required nasojejunal feeding and fundoplication.
He had repeated hospital admissions during infancy for
respiratory tract infections and has nocturnal ventilation with
bilevel positive airway pressure overnight. He had surgery for
severe kyphoscoliosis at the age of 2.5 years. He had motor
delay and sat unaided at the age of 2 years. At the age of 4
years he can stand and walks with support, only. His most
recent hearing test showed moderate conductive hearing loss
and hypermobile tympanic membranes.
Sanger sequencing confirmed that both siblings are
homozygous for the c.197 + 5_197 + 8del mutation in intron
1 of FKBP14. Both parents were confirmed to be heterozygous
carriers of the mutation. Transcript analysis on total RNA
extracted from cultured fibroblasts of P5/FIV revealed that the
identified deletion of 4 nucleotides in intron 1 of the genomic
sequence of FKBP14 leads to the insertion of 17 nucleotides in
the transcript of FKBP14 in between exons 1 and 2 and to a
new open reading frame from c.198 on and a p. His67*
premature termination codon (CAC >TAA).
Patient P17/XV
This 11-month-old boy presented with micrognathia and
clenched hands on antenatal ultrasound.
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Figure 1 Clinical phenotype of patients with FKBP14-kEDS. Consent for publication of patient photos was obtained for each subject. (a,b) P1
from the original publication4 showing wrist-drop of both hands in early infancy (a,b, age 2 and 6 weeks). (c) P3/FIII at age 10 years after surgical
correction of the severe thoracolumbar scoliosis. (d) P2/FII at age 8 years after surgical correction of the progressive severe scoliosis. (e) P1/FI at age 8
years with pes planovalgus and rocker bottom feet. (f,g) P7/FV showing micrognathia (f, age 1 year), and hyperextensible skin (g, age 8 years). (h) P10/
FVIII at age 12 years with pronounced pes valgus. (i) P12/FX at age 8 years presenting with pectus excavatum. (j–l) P13/FXI at age 5 years presenting
with pectus excavatum, umbilical herniae, and wrinkly, redundant skin (j), pronounced criss cross pattern of the soles (k) and cutis marmorata (l). (m–o)
P8/FVI at age 6 years (m,o), and 8 years (n) showing scoliosis (m), hyperkeratotic skin eruptions in the pressure areas under the thoracolumbar orthosis
(o), and mild flexion contractures of the elbows (n).
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Postnatally he was found to have hypotonia, Pierre Robin
sequence, camptodactyly of his second and third fingers
bilaterally, and bilateral positional talipes equinovarus. After
delivery he was transferred to the neonatal unit due to
problems maintaining his saturations. He was initially
managed with a nasopharyngeal airway and was fed by
nasogastric tube due to concerns about his poor gag reflex.
Oral feeding has subsequently been introduced. Newborn
screening suggested a mild sensorineural loss on the left but
more recent audiology shows normal bone conduction and a
moderate hearing loss of 40 dB due to a middle ear effusion.
An echocardiogram at a month of age showed a pseudo
bicuspid valve, small muscular ventricular septal defect,
normal cardiac function, and dilatation of the ascending
aorta. A later echocardiogram at 10 months in addition
showed a small atrial septal defect and aortic dilatation with a
Z score of + 3.75 just beyond the tubular junction. At
9 months he was noted to have a mild thoracolumbar
scoliosis to the left, which was confirmed on X-ray. On
examination he was hypotonic and had just gained head
control. He was not yet able to sit. The skin was hyper-
extensible with no evidence of scarring and no bruises. Next-
generation sequencing for a set of selected genes (ACTA2,
COL1A1, COL1A2, COL3A1, COL5A1, COL5A2, EFEMP2,
FBN1, FBN2, FKBP14, FLNA, HNRNPK, MED12, MYH11,
MYLK, NOTCH1, PRKG1, SKI, SLC2A10, SMAD3, SMAD4,
TGFB2, TGFB3, TGFBR1 and TGFBR2) identified the
common mutation c.362dupC p.(Glu122Argfs*7) in FKBP14.
The parents were heterozygous for the identified variant.
Biochemical, neuromuscular, and laboratory investigations
(Supplementary Table S1)
The results of laboratory, biochemical, and neuromuscular
analyses are summarized in Supplementary Table S1.
Follow-up and additional findings in three previously
published patients (Supplementary Table S2)
The previously reported clinical features of patients P1, P2,
and P6,4 along with additional findings at follow-up, are
summarized in Supplementary Table S2. At the age of 50
years P2 of the original publication developed an extracranial
dissection of the right internal carotid artery (Figure 2a–c).
The event occurred during a respiratory infection with intense
coughing. The lesion was located just above the carotid artery
bifurcation with formation of a pseudoaneurysm extending to
the base of the skull. No cerebral infarction occurred and
treatment was nonsurgical. Investigations further revealed
elongation and increased tortuosity of the extracranial cervical
vessels, dilatation of the ascending aorta, and mild mitral
and pulmonary valve insufficiency. Echocardiography showed
normal systolic and diastolic ventricular function and no signs
of cardiomyopathy. Repeat MRI angiography after 9 months
showed no residual pseudoaneurysm of the carotid artery but
a small pseudoaneurysm of the right vertebral artery.
Because of progressive scoliosis, patient P6 underwent a
spinal MRI at age 4 years, which revealed an atlantoaxial
subluxation with dens dislocation and myelocompression
(Figure 2d,e). Consecutively, the craniocervical junction
was surgically stabilized with dorsal instrumentation.
Neurological complications did not occur and at last follow-
up at the age of 9 years she was in a stable neurological
condition.
At age 16 years, patient P1 presented with exacerbation of
the kyphoscoliosis with severe thoracic deformity resulting in
restrictive lung disease. A dorsal thoracolumbar distraction
spondylodesis was performed at the age of 17 years after
preoperative treatment with halo and sling traction. Sub-
sequent to surgery a height gain of 9 cm was documented, and
a considerable improvement of pulmonary function (increase
in forced vital capacity from 47 to 66%) and endurance was
achieved.
Echocardiography performed at the age of 19 years showed
diameters of the aortic root and the ascending aorta at the
upper normal limit (Z score 1.8) without irregularities of the
wall. Echocardiography control and cardiac MRI at the age of
21 years showed a slight increase of the diameters, now above
the upper normal limit (Z score 2.2).
DISCUSSION
FKBP14-kyphoscoliotic EDS (FKBP14-kEDS), caused by
biallelic mutations in FKBP14, represents one of the differ-
ential diagnoses of PLOD1-kyphoscoliotic EDS (PLOD1-
kEDS, EDS VIA). In the first description six genetically
proven and one likely affected individual were reported with
this ultrarare connective-tissue disease.4 Meanwhile, three
additional patients have been delineated,5,6,18 showing that the
phenotypic spectrum may be broader than initially antici-
pated in the original publication, and raising the risk for a life-
threatening cardiovascular phenotype. Based on our results, as
summarized in Table 2, the major diagnostic criteria are
(i) severe generalized hypotonia at birth with marked muscle
weakness that improves in infancy, and delayed gross motor
milestones; (ii) early-onset progressive (kypho)scoliosis;
(iii) joint hypermobility without pronounced contractures;
(iv) foot deformities; and (v) normal or decreased ratio of
lysyl pyridinoline to hydroxylysyl pyridinoline in urine.
Minor criteria include (i) hyperelastic skin with follicular
hyperkeratosis, easy bruising, and occasional abnormal
scarring; (ii) myopathy as seen clinically by reduced strength
and endurance and confirmed in some patients by histology
and muscle imaging; and (iii) hearing impairment that is
predominantly sensorineural and may not be present in all
individuals. This information was seminal to the redraft of the
2017 International Nosology of EDS.3
Occasional features underlying systemic connective-tissue
involvement are aortic rupture and arterial dissection,
subdural hygroma (potentially due to subdural bleeding or
spontaneous intracranial hypotension),19 insufficiency of
cardiac valves, bluish sclerae, bladder diverticula, inguinal or
umbilical herniae, and premature rupture of membranes.
We now add the clinical, biochemical, and molecular
description of 17 additional patients, and describe new clinical
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features uncovered in three patients, originally published
in 2012.4 This observational data emphasizes the clinical
features, allowing for the definition of major and minor
diagnostic criteria and adds insight into the clinical variability
of the disease. It is certainly of note that the molecular
diagnosis in the majority of the patients was achieved by
direct Sanger sequencing of FKBP14 due to the strong
suggestive clinical features.
The risk of vascular complications in FKBP14-kEDS was
initially suspected based on the history of aortic rupture in the
12-year-old sibling of a proven affected patient (P2).4 She had
shared characteristic clinical features with her similarly
affected sister but had died prior to molecular testing. The
follow-up in her sister at the age of 50 years revealed an
internal carotid artery dissection. This finding strongly
supports the suspicion of a vascular phenotype of FKBP14-
kEDS; vascular complications including a dissection of the
celiac artery at age 41 years6 and a hypogastric artery
pseudoaneurysm rupture at age 6 years5 were described
recently. Therefore awareness for possible serious vascular
complications in different age groups in patients with
FKBP14-kEDS should be raised, and vascular screening
already starting at pediatric age should be included into the
surveillance of these patients.
a b
d
c
e
Figure 2 Radiological findings. At the age of 50 years, P2 from Baumann et al.4 developed a dissection of the internal carotid artery. The perforation
was located just above the right carotid artery bifurcation with formation of a pseudoaneurysm extending to the base of the skull. (a) Contrast-
enhanced magnetic resonance angiography shows interruption of the right internal carotid artery (double arrowhead) and elongation and increased
tortuosity of the extracranial vessels. Axial sections with (b) fat saturated T1 sequences and (c) time-of-flight angiography show the residual lumen of
the right internal carotid artery (double arrowhead). Spinal magnetic resonance image at age 4 years in P6 from Baumann et al.4 shows an atlantoaxial
subluxation with dens dislocation and myelocompression. (d) In sagittal T2-weighted imaging compression of the spinal canal and increased signal
intensity of the myelon at the craniocervical junction as sign of myelopathy (double arrowhead). (e) Axial T1-weighted imaging shows dislocation of the
dens with myelocompression (double arrowhead) and pannus proliferation around the dens.
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Clinical follow-up of the initial cohort4 revealed a new
skeletal feature in one patient. Symptomatic atlantoaxial
subluxation with dens dislocation and myelocompression
requiring a posterior occipitocervical fixation was found in P6
at age 4 years. Asymptomatic atlantoaxial instability was
recently reported in a 6-year-old patient,5 but not in any other
patient known so far, although not all had radiological
investigations aimed to investigate this feature. Occipitoa-
tlantoaxial hypermobility and instability has been described in
other types of EDS, in particular in the classic, hypermobile,
and vascular type.20–23
In the vast majority of the patients of this cohort the hands
have a normal appearance (Supplementary Figure S1).
Limb contractures were not observed in the initial patient
group4 and the three single patients delineated subse-
quently.5,6,18 However, the cohort presented here includes
seven patients with prominent congenital contractures of
fingers, wrist, elbows, or knees. Although the natural history
of the contractures cannot be predicted yet, amelioration was
documented in half of the affected, whereas two remained
symptomatic at the age of 9 and 15 years, respectively. More
pronounced contractures are a feature of the musculocon-
tractural type of EDS24 and the collagen VI–related
myopathies in which they are often progressive.9,12 Further-
more, extension deficit of the elbow/congenital flexion
contractures are nosology criteria for the Marfan.25
Midline defects of the palate or lips are only sporadically
described in EDS.26–28 However, bifid uvula and cleft palate,
which are frequently found in Loeys–Dietz syndrome,29
have been observed in FKBP14-kEDS patients. A cleft of the
soft palate was observed in two patients of the first patient
group, and a bifid uvula in the patient described by Dordoni
et al.5 In the actual patient cohort, cleft palate, defined as
bifid uvula with submucous cleft palate or wide cleft palate,
was found in five patients. Therefore, these observations raise
the question of whether Marfan spectrum disorders, in
particular Loeys–Dietz syndrome, should be considered in
the differential diagnosis of FKBP14-kEDS. However, cleft
palate might also occur secondary to micrognathia and
retrogenia as described in three of the five patients with
cleft palate in the actual cohort (P4/FIII, P5/FIV, and P17/
FIV). Hearing impairment, in particular sensorineural
hearing loss, was initially described as a characteristic clinical
feature of the disorder based on the findings of the
initial cohort.4 Extended descriptions of additional patients
indicate that this feature might be less prominent as initially
suggested, as 41% currently present with sensorineural
hearing impairment. However, in 18% of the patients of the
present cohort, conductive hearing loss was diagnosed.
Therefore, hearing impairment, although less common than
previously considered, still represents a diagnostic feature of
FKBP14-kEDS. This can manifest at birth or in early infancy,
or even later in life. We should point out that the mainly
younger age of the patients in this cohort might represent a
limitation of our study in regard to the frequency of hearing
impairment.
The majority of the patients in this cohort presented with
congenital hypotonia and weakness, which improved during
childhood. All had delayed motor developmental and reduced
muscle strength, and the age of unassisted walking was delayed
in all, ranging from 2 to 7 years. Nerve conduction measured in
10 patients was normal in all. Unspecific myopathic changes
were found on muscle biopsies and/or electromyography in five
patients, whereas muscle biopsy and/or electromyography in six
patients were normal. In one patient a repeated electromyo-
graphy showed an improvement of the myopathic features, and
in another patient who presented repeatedly with myopathic
alterations at ages 3 months and 1 year, a third electromyo-
graphy was normal at age 8 years. Creatine kinase was normal
and thus not to be used as a discriminating biomarker, from
Bethlem myopathy and Ullrich myopathy. However, Bethlem
myopathy and Ullrich congenital muscular dystrophy have
distinct patterns of muscle involvement on MRI, which have
not been seen in FKBP14-kEDS. Muscle MRI was performed in
three patients and revealed mild atrophy of the rectus femoris,
and mild hypertrophy of the vastus medialis in one of them.
The clinical symptoms suggesting a myopathy are most likely
caused by secondary effects of the connective alterations in
and around muscle, with secondary effects on muscle fibers
themselves, as is in fact the case in the COL6-related dystro-
phies,30 and thus not due to a primary myofiber involvement.
However, in contrast to the COL6-related dystrophies, in
FKBP14-kEDS this matrix abnormality does not appear to
result in progressive muscle degeneration. Similar neuromus-
cular findings are also seen in other EDS types in particular in
PLOD1-kEDS (EDS VIA). The natural course of the neuro-
muscular phenotype is yet to be defined. Reduced motor
function and fatigue in adulthood was only reported in two
adult patients4,6 and might represent an age-dependent feature
in the natural course of FKBP14-kEDS.
Mild intellectual disability and/or learning difficulties have
been documented in the siblings of family III and in patient
P14/XII. However, in absence of additional data, we should
consider that impaired cognitive development in these
patients might have a different genetic cause due to parental
consanguinity.
The management of patients affected with FKBP14-kEDS,
with focus on the musculoskeletal, the cardiovascular, and
the hearing systems, and the molecular genetic confirmation
of the diagnosis, should follow the guidelines of the 2017
International Nosology of EDS.3
Ishikawa and Bächinger14 recently published evidence
supporting the involvement of FKBP14, alias FKBP22, in
the molecular ensemble for type III, type VI, and type X
collagen maturation, showing that the protein interacts with
these types of collagens. Remarkably, mutations in type III
and type VI collagens are the genetic hallmark of the vascular
type of EDS (vEDS) and of COL6-related dystrophies, respec-
tively. Therefore, the clinical features of vascular abnormal-
ities and myopathy documented in the affected individuals
clearly correlates with the interaction of FKBP14 with type III
and VI collagens.
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Complete or partial loss of function of FKBP14 as the
crucial disease mechanism of the disorder is suggested by
mapping of the first identified missense variant p.(Met48Lys)
onto the protein crystal structure (Supplementary Figure
S4B). The p.Met48Lys variant maps near the potential PPIase
active site of the FKBP domain. Replacement of the hydro-
phobic methionine by the positively charged lysine may
selectively impair the PPIase activity without affecting
chaperone function.
In summary, the review of the present patient cohort, the
follow-up of three patients from our initial publication as well
as the comparison with all published cases, reveals a quite
consistent clinical presentation of the disorder and allows us to
speculate on major and minor clinical criteria. In contrast to the
broader clinical spectrum of phenotypic presentation
in PLOD1-kEDS, FKBP14-kEDS thus far presents with a less
pronounced phenotypical variability. Vascular complications in
adulthood should be considered as a disease-related feature,
Table 2 Features associated with FKBP14 mutations in our two patient cohorts (frequency reported as percentage)
Cohorts Present study Baumann et al.4 a Total Percentage
Total number of patients 17 6 23
Skin
Hyperextensible 12/17 5/6 17/23 73
Soft texture 16/16 6/6 23/23 100
Criss cross palms/soles 5/17 NR 5/17 29
Follicular hyperkeratosis 6/16 4/6 10/23 43
Easy bruising 7/16 3/6 10/23 43
Hypertrophic scars 3/17 1/6 4/23 17
Atrophic scars 2/17 1/6 3/23 13
Joints and skeleton
Hypermobile large joints 15/17 6/6 21/23 91
Hypermobile small joints 17/17 6/6 23/23 100
Congenital hip dislocation 4/17 NR 4/17 23
Recurrent dislocations 4/17 1/6 5/23 21
Joint contractures 7/17 0/6 7/23 30
Progressive kyphoscoliosis 14/17 4/6 18/23 78
Foot deformities 17/17 6/6 23/23 100
Fractures 2/17 1/6 3/23 13
Neuromuscular
Muscle hypotonia at birth 17/17 6/6 23/23 100
Poor head control in infancy 17/17 6/6 23/23 100
Weakness improving 16/16 6/6 22/22 100
Delayed motor development 17/17 6/6 23/23 100
Muscular atrophy 8/16 6/6 14/22 63
Cardiovascular
Cardiac valve abnormalities 6/16 3/6 9/22 40
Septum defects 3/16 0/6 3/22 13
Vascular abnormalities 4/14 2/6 6/20 30
Eyes and ears
Bluish sclerae 7/17 1/6 8/23 34
Refraction anomaly 9/14 3/6 12/20 60
Hearing impairment 11/17 6/6 17/23 73
Miscellaneous
Cleft palate, bifid uvula 5/17 2/6 7/23 30
Micrognathia, retrognathia 6/17 2/6 8/23 34
Herniae 7/17 4/6 11/23 47
Bladder diverticulum 1/15 2/4 3/19 15
Speech or language delay 7/17 0/3 7/20 35
Learning difficulties/intellectual disability 3/17 1/6 4/23 17
NR, not recorded.
aIncluding follow-up in three patients.
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and their possible occurrence in childhood urges cardiovascular
investigations in the routine assessment and follow-up of these
patients. Hearing impairment, either conductive or sensori-
neural, might manifest later in life or remain subclinical, thus
requiring periodic investigations. Motor developmental delay
and reduced motor strength are common neuromuscular
features in childhood, and a decline of motor function in
adulthood seems to represent an age-dependent feature in the
natural course of FKBP14-deficient EDS.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the
paper at http://www.nature.com/gim
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